Eveliqure Biotechnologies is an innovative biotech company dedicated to tackling the prevention of diarrheal diseases in both travelers and individuals residing in low- and middle-income countries where these diseases are endemic. With a focus on vaccine development, Eveliqure has developed a cutting-edge vaccine technology platform utilizing a live attenuated vaccine strain of the bacterium Shigella. This technology is engineered to provide broad protection against various species and serotypes of this pathogen.

An advancement in the field, Eveliqure has also incorporated non-shigella derived antigens into the strain to achieve protection against multiple pathogens. Their first-generation vaccine candidate, ShigETEC, targets both Shigella and enterotoxigenic Escherichia coli (ETEC), two of the primary culprits behind diarrheal infections. The name Eveliqure is a combination of Endovelicus, the Celtic god of public health, and liquid, symbolizing a drinkable vaccine.

With a clear vision and mission, a talented management team, and headquarters located in Vienna, Austria, Eveliqure is at the forefront of developing smarter vaccines to combat diarrheal diseases